Skip to content

CLIA Beta 2 Glycoprotein IgM

by TestLine Clinical Diagnostics s.r.o. EUDAMED

Active European Union

Ref CL-BGM100

Regulatory status

as of 26 Oct 2026

RegionAuthorizationNumberDateStatus
European UnionCE/IVDR Number8595635312229C7 Basic UDI-DIDate2 Sep 2026RegisteredStatusActive

Coverage

1 jurisdiction

SwedenFinlandFinlandSwedenFinlandFinlandSwedenSwedenLatviaEstoniaDenmarkLithuaniaIrelandNetherlandsGermanyGermanyPolandPolandFranceBelgiumLuxembourgCzech RepublicSlovakiaPolandFranceFranceAustriaHungaryRomaniaFranceFranceSloveniaBulgariaPortugalSpainSpainItalySpainSpainCroatiaGreeceMaltaCyprus
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not known
  • Not covered

European Union — CE/IVDR Active

Certificates: none listed in EUDAMED

Specification

EUDAMED

Device Name
CLIA Beta 2 Glycoprotein IgM
Model / Reference
CL-BGM100
Primary DI / UDI-DI
08595635312229
Basic UDI-DI
8595635312229C7
EMDN Code
W0102100503 Anti-b2-glycoprotein i antibodies
Device Class
Class B
Market of Registration
Czechia

Manufacturer details

EUDAMED SRN
CZ-MF-000001803

Other devices from TestLine Clinical Diagnostics s.r.o.

See all devices from TestLine Clinical Diagnostics s.r.o. →

Properties

Show properties
  • Human Tissues
  • Animal Tissues
  • Reagent
  • Professional Testing
Other properties (7)
  • Sterile: No
  • Microbial Substances: No
  • Self Testing: No
  • Near-Patient Testing: No
  • Companion Diagnostics: No
  • Surgical Instrument: No
  • New Device: No